DailyIQ
Last updated1 minute ago

GILD·Gilead Sciences, Inc.

$153.56
+5.64 (+3.81%)
High
$153.76
Open
$148.19
Market Cap
184.77B
52W High
$157.29
Low
$147.48
P. Close
$153.56
P/E
21.71
52W Low
$112.06
Fwd P/E
14.89
DailyIQ Est.
$164.99
Inst. Ownership
48.0%
Short Interest
1.75%
Days to Cover
3.4
Div. Yield
2.20%
Next Ex-Div
~Dec 15
Div. Growth
10+ yrs
Technical Score (1D)
69
BULLISH
News Sentiment
41
BEARISH
On Oct 13, Gilead Sciences was set to release its Q3 earnings report. Analysts had projected a double‑digit year‑over‑year decline in earnings per share. The forecast reflected ongoing challenges in the company’s drug portfolio and competitive pressures. Investors were expected to focus on the guidance and any commentary on future growth prospects. The preview highlighted that the decline would signal continued difficulties in Gilead’s pipeline, underscoring the importance of the upcoming earnings for assessing the company’s trajectory.
LOW TARGET
$126 -17.9%
1 analysts
MEAN TARGET
$160 +4.0%
22 analysts
HIGH TARGET
$180 +17.2%
16 analysts
PRICE RANGE
$126.00 - $180.00
SB / B / H / S / SS
9/21/7/1/1
DAILYIQ EST.
$164.99 (+7.4%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NMS
Country
United States
Website
Symbol
GILD
Description
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and marketing medicines to address significant unmet medical needs globally. The company's core business centers on treatments for viral diseases, including HIV/AIDS and hepatitis, with a portfolio of established therapies such as Biktarvy, Genvoya, and Epclusa. Beyond virology, Gilead offers oncology products like Yescarta and Trodelvy, as well as treatments for pulmonary arterial hypertension and invasive fungal infections. Gilead leverages strategic collaborations with other pharmaceutical and biotechnology companies, including Arcus Biosciences and Merck, to expand its research and development capabilities and pipeline of potential future therapies. Founded in 1987, the company is headquartered in Foster City, California.
Bought (1Y)
0 shares
$0
Sold (1Y)
196,589 shares
$26.9M
O'Day Daniel PatrickChairman & CEO
Sell3,000 shares2026-10-01
O'Day Daniel PatrickChairman & CEO
Sell12,000 shares2026-10-01
Burkhart ErinSVP, Controllership
Option Exercise2,223 shares2026-09-22
Burkhart ErinSVP, Controllership
Tax Withholding768 shares2026-09-22
Burkhart ErinSVP, Controllership
Option Exercise2,223 shares2026-09-22
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
78.8%
Net Margin
28.9%
Revenue CAGR
11.4%
Current Ratio
1.55x
Debt / Equity
1.10x
Return on Equity
37.5%
Earnings Summary
Gilead Sciences, a biopharmaceutical company headquartered in Foster City, California, specializes in antiviral therapies for HIV/AIDS and hepatitis, while also offering oncology and rare disease treatments. Operating within the broader healthcare drug manufacturing sector, Gilead has historically leveraged strategic collaborations to expand its pipeline and market reach. In the most recent quarters, the company reported Q4 2025 revenue of $7.925 billion, up from $6.667 billion in Q1 2025, and Q2 2026 revenue of $7.803 billion, a modest increase over Q1 2026’s $6.960 billion. EPS trends show a slight decline in Q4 2025 to $1.86 from $2.01 in Q3 2025, while Q1 2026 EPS rose to $2.03 from $1.81 in Q1 2025, indicating a mixed pattern of earnings growth. The company has consistently beat analyst EPS estimates in three of the last four quarters, though the Q4 2025 EPS miss relative to the $1.984 estimate highlights volatility. Historically, Gilead’s revenue has grown YoY, with a 12% increase in Q3 2025 versus Q3 2024, yet EPS has fluctuated due to margin pressures. Notably, the firm has maintained revenue growth even when EPS fell short, underscoring a resilient sales base. Recent news from October 2024 highlighted analyst concerns over a projected double‑digit YoY decline in EPS, reflecting ongoing pipeline challenges and competitive pressures; however, the October 11 report noted robust Q2 sales driven by the HIV portfolio, suggesting that revenue momentum may outpace margin compression. Key will be the company’s ability to sustain revenue growth while addressing margin erosion and maintaining a positive earnings trajectory.

EPS

EstBeatMiss
$-8.86$-5.66$-2.45$0.75$3.95Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.19 - -
Q2'26$-7.38$-6.75+8.5%
Q1'26$1.95$2.03+4.0%
Q4'25$1.98$1.86-6.2%
Q3'25$2.14$2.47+15.7%
Q2'25$1.96$2.01+2.7%

Revenue

EstBeatMiss
$6.8B$7.1B$7.4B$7.8B$8.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$7.9B - -
Q2'26$7.5B$7.8B+3.4%
Q1'26$7.1B$7.0B-1.3%
Q4'25$6.9B$7.9B+14.1%
Q3'25 - $7.8B -
Q2'25 - $7.1B -

Market Data

GILD Stock Snapshot

BULLISH69/100
$153.56+$5.64 (3.8%)
Market cap
184.77B
P/E ratio
21.7
Day range
$147.48 – $153.76
News sentiment
41/100 · Neutral
Analyst target
$159.62 (+3.9%)
Consensus
Buy · 39 analysts
52-week range+37.0% off low · -2.4% from high
$112.06$157.29
Price $153.56 DailyIQ Est. $164.99

GILD is trading with the trend behind it, which is what pushes the technical read bullish. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into GILD?

CHEAP

At today's price, Gilead Sciences, Inc. needs to grow free cash flow about 4.4% a year for the next 10 years to justify its valuation at a 7.74% cost of capital. Over its actual history it has compounded free cash flow at 9.8% a year, so the market is asking for 5.4 percentage points below its own delivered rate. On that basis GILD looks priced below what its own growth record supports.

Implied FCF growth
4.4%
Historical FCF CAGR
9.8%
Growth gap
-5.4 pts
Verdict
CHEAP
Discount rate (WACC)
7.74%
Beta
0.61

Behaviour On Record

What GILD's own history says about today's numbers

Realized volatility (21d)
20.0% 33rd pct
Below its peak
-5.2%
vs 200-day average
+7.4%
Up days (1y)
48%

Gilead Sciences, Inc. is currently running 20.0% annualised volatility over the last 21 sessions. Measured against GILD's own 13 years of daily returns rather than a market-wide average, that is the 33rd percentile — on the quiet side for this stock, against a typical reading of 22.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

GILD is trading -5.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -36.5% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +7.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 70th percentile — a somewhat wider gap than its own norm. Over the past year GILD closed higher on 48% of sessions, and it is currently 3 sessions into a falling streak.

On October specifically: over 14 years of records, GILD finished the month higher 9 of 14 times, with a median return of +3.1% and an average of +2.2%. Its strongest month historically has been January at +3.3% on average, its weakest December at -2.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: GILD has opened more than 2% away from the prior close in 30 of 3,268 sessions (0.9% of the time), with the largest gaps running +3.3% and -5.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, GILD moved an average of 3.1% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.7% and a largest of +7.2%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against GILD's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of GILD's sector?

Gilead Sciences, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for GILD?

CallsPuts

For Gilead Sciences, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.67), with at-the-money implied volatility around 37.3%. The options market is pricing roughly a ±2.6% move by that expiry — a range of about $149.27–$157.39.

Put/call ratio (2026-10-16)
0.67
ATM implied volatility
37.3%
Total open interest
15,896
Expected move by 2026-10-16
±2.6% ($149.27–$157.39)

Analyst Rating Changes

Are analysts turning bullish or bearish on GILD?

RBC Capital most recently reiterated its rating on Gilead Sciences, Inc. to Sector Perform on Oct 8, 2026 with a price target of $126 (from $123). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
RBC Capital — Sector Perform
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Oct 8, 2026RBC CapitalMaintainedSector Perform$123 → $126
Oct 8, 2026Cantor FitzgeraldReiteratedOverweight$155
Oct 7, 2026Truist SecuritiesMaintainedBuy$150 → $158
Oct 7, 2026JP MorganMaintainedOverweight$160 → $170
Oct 7, 2026Morgan StanleyMaintainedOverweight$165 → $163
Sep 10, 2026HSBCMaintainedBuy$155 → $175
Aug 5, 2026RBC CapitalMaintainedSector Perform$120 → $123
Aug 5, 2026Cantor FitzgeraldReiteratedOverweight$155
Aug 5, 2026NeedhamReiteratedBuy$170
Jul 29, 2026BarclaysMaintainedEqual-Weight$155 → $145
Jul 27, 2026Morgan StanleyMaintainedOverweight$166 → $165
Jul 21, 2026Leerink PartnersDowngradeOutperform → Market Perform$146 → $127

Peers & ETF holders

GILD peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

41/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Gilead Sciences is scheduled to release its Q3 earnings report, with analysts projecting a double‑digit year‑over‑year decline in earnings per share. The forecast reflects ongoing challenges in the company’s drug portfolio and competitive pressures. Investors will be watching the guidance and any commentary on future growth prospects.
What did this article say?
Gilead Sciences closed at $151.17 on October 9, trailing Biogen and Amgen in six‑month returns. The company reported a net loss exceeding three billion dollars over the past year, yet still generated the highest cash flow among the trio. The loss is attributed to write‑downs and acquisition charges rather than declining sales. This financial performance signals a modest headwind for Gilead relative to its competitors.
What did this article say?
Bank of America analysts reviewed a survey on Gilead Sciences’ new drug Yeztugo and concluded the data supports the company’s long‑term growth outlook. The survey indicated positive patient and provider sentiment, suggesting continued demand for the therapy. The assessment reinforces Gilead’s strategic positioning in the oncology market and aligns with recent guidance. No immediate impact on earnings guidance was noted, but the findings may influence investor perception of the company’s growth trajectory.
What did this article say?
Gilead Sciences (GILD) reported a 10% rise in Q2 sales, contributing to a 24% year‑to‑date share price increase that outpaced the S&P 500’s 14%. The company’s portfolio of HIV, liver disease and cancer therapies continued to drive revenue growth. Analysts noted that the robust performance positioned GILD among the top performers in 2026, reinforcing investor confidence.
What did this article say?
BofA Securities increased its price target for Gilead Sciences to $168 from $162, reflecting a modest upside expectation. The brokerage maintained a buy rating, indicating confidence in the company’s earnings outlook. The adjustment suggests BofA believes Gilead’s recent developments and pipeline prospects support a higher valuation.
What did this article say?
Gilead Sciences reported a 24% year‑to‑date stock gain, outperforming the S&P 500’s 14% return. Analysts noted the company’s normalized forward P/E of about 15.5, based on adjusted earnings that exclude acquisition‑related charges. The valuation discussion centers on whether the underlying growth of its core HIV business can justify the multiple. The article also highlights that nine other healthcare stocks rank higher in a hedge‑fund list of attractive picks.
What did this article say?
Gilead Sciences posted robust Q2 sales, particularly in its HIV portfolio, underscoring revenue growth potential. However, the company reported weaker earnings, suggesting margin compression or higher costs. Analysts noted that while sales momentum remains, profitability concerns could temper investor enthusiasm. The company’s long‑term performance remains solid, but short‑term earnings volatility may influence valuation.
What did this article say?
Gilead Sciences closed the day at $151.17, up 2.77% and outperforming the S&P 500. The company’s stock has gained 1.58% over the past month, leading the medical sector. Analysts expect next quarter earnings of $2.14, a 13.36% decline from the prior year, while revenue is projected to rise 0.51%. The annual consensus forecasts a loss of $0.48 per share and a modest revenue increase of 4.47%. Investors are watching the upcoming earnings release for further guidance.
What did this article say?
Gilead Sciences reported Q2 revenues of $7.80 billion, a 10.2% year‑over‑year increase, surpassing analyst expectations. The company’s diversified portfolio, including HIV, viral hepatitis, COVID‑19, and oncology products, contributed to the growth. Sector‑wide gains were driven by precision medicine advances, though pricing scrutiny and regulatory uncertainty remained potential risks.

Technical Analysis

Real-time indicators across multiple timeframes

69
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $74.60B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy121,844,1089.74%$15.39B2026-08-07
Vanguard Group Inc▲ Buy121,097,3369.68%$14.86B2026-01-29
FMR LLC (Fidelity)▼ Sell66,870,8165.35%$8.45B2026-08-13
Capital World Investors▼ Sell40,988,9753.28%$5.18B2026-08-12
Invesco Ltd.▲ Buy39,819,1513.18%$5.03B2026-08-14
Geode Capital Management, LLC▲ Buy30,065,6422.40%$3.80B2026-08-12
Morgan Stanley▲ Buy24,004,3541.92%$3.03B2026-08-13
Norges Bank▲ Buy21,965,5551.76%$2.78B2026-08-12
JPMorgan Chase & Co▼ Sell20,820,6211.66%$2.63B2026-08-12
Capital Research Global Investors▼ Sell19,393,2961.55%$2.45B2026-08-12
Bank of America Corp▼ Sell18,649,0651.49%$2.36B2026-08-14
Northern Trust Corp▲ Buy13,828,0101.11%$1.75B2026-08-13
Wellington Management Group LLP▼ Sell12,699,6831.02%$1.60B2026-08-14
Goldman Sachs Group Inc▼ Sell10,778,2940.86%$1.36B2026-08-14
Wells Fargo & Company▼ Sell6,439,5860.51%$813.58M2026-08-14
AllianceBernstein L.P.▼ Sell4,613,3830.37%$642.97M2026-08-14
Citadel Advisors LLC▼ Sell3,480,4440.28%$439.72M2026-09-02
Citigroup Inc▲ Buy2,969,1590.24%$375.12M2026-08-03
D. E. Shaw & Co., Inc.▲ Buy2,294,7890.18%$289.92M2026-08-14
Renaissance Technologies LLC▲ Buy2,217,3760.18%$280.14M2026-08-13
Janus Henderson Group plc▲ Buy1,972,6390.16%$274.92M2026-05-18
Squarepoint Ops LLC▲ Buy1,823,2240.15%$230.35M2026-08-14
Prudential Financial Inc▲ Buy1,759,3490.14%$222.28M2026-08-12
Millennium Management LLC▲ Buy1,458,9240.12%$184.32M2026-08-14
Point72 Asset Management, L.P.▲ Buy1,437,6850.11%$181.64M2026-08-14
Q2 2026 flow:24.93M sh bought ($3.15B)30.50M sh sold ($3.87B)net -5.57M sh (−$718.05M)
Congressional Trading Activity
25 disclosed trades · ~$249.0K est. traded value · 15 buys, 10 sells
MemberChamberStateTypeAmountTradedFiled
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2026-05-062026-06-19
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Josh GottheimerHouseNJ05▲ Buy$1K - $15K2026-01-272026-02-26
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-06-062025-06-18
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-05-142025-06-11
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-05-052025-05-06
John BoozmanSenateAR▼ Sell$1K - $15K2025-04-162025-05-14
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-03-312025-04-11
Carol Devine MillerHouseWV01▲ Buy$1K - $15K2025-03-102025-04-11
Josh GottheimerHouseNJ05▲ Buy$1K - $15K2025-03-072025-04-10
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12
Tommy TubervilleSenateAL▲ Buy$1K - $15K2024-05-102026-08-05
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-05-082026-08-05
Tommy TubervilleSenateAL▲ Buy$1K - $15K2024-04-052024-05-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-04-032024-05-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-01-132022-02-14
Jerry MoranSenate-▼ Sell$1K - $15K2021-12-212022-01-21
Jerry MoranSenate-▲ Buy$1K - $15K2020-08-212020-09-08
Jerry MoranSenate-▲ Buy$1K - $15K2019-09-252020-08-05
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2019-03-112019-04-17
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2018-09-252018-10-18
Angus KingSenate-▼ Sell$1K - $15K2018-04-232018-05-22
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2017-10-252017-11-07